Predictive medicine company PreMD Inc. has announced that it has filed a provisional patent application that describes a new simplified method of quantifying immunohistochemical staining of biomarkers. The provisional patent application was filed with the United States Patent and Trademark office. This application, based on PreMD’s existing colour measurement patents and patent applications, may
Full Post: PreMD files provisional patent application for new method of quantifying cancer biomarkers
A study led by researchers at The University of Nottingham has identified a gene that protects the body from lung cancer.
The research, published in the journal Proceedings of the National Academy of Sciences, USA and funded by a £72,000 grant from the British Lung Foundation, has found that the tumour suppressor gene, LIMD1, is responsible for protecting the body from developing lung cancer - paving the way for possible new treatments and early screening techniques.
Lead researcher Dr Tyson Sharp and his University of Nottingham team, together with US collaborator Dr Greg Longmore, set out to examine if loss of the LIMD1 gene correlated with lung cancer development.
The University of Nottingham team examined lung cancer tissue from patients with the disease and compared it to healthy lung tissue. They found that the LIMD1 gene was missing in the majority of lung cancer samples, indicating that the presence of the LIMD1 gene protects the body against lung cancer.
Dr Greg Longmore’s team in the USA supported these findings, using a mouse without the LMID1 gene which developed lung cancer.
Dr Sharp said: “The LIMD1 gene studied in this research is located on part of chromosome 3, called 3p21.
“Chromosome 3p21 is often deleted very early on in the development of lung cancer due to the toxic chemicals in cigarettes, which implies that inactivation of LIMD1 could be a particularly important event in early stages of lung cancer development.
“We are now going to extend these finding by developing LIMD1 as a novel prognostic tool for detection of early stage lung cancer.”
Lung cancer is the UK’s biggest cancer killer, claiming around 33,600 lives a year. Ninety per cent of cases are caused by smoking. At present lung cancer is often detected late, meaning that 80 per cent of patients die within a year of being diagnosed.
Dame Helena Shovelton, Chief Executive of the British Lung Foundation said: “This is very exciting research which could lead to the development of early screening techniques and treatments for lung cancer. We are very proud to have made this breakthrough possible”.
http://www.nottingham.ac.uk/
--------------------------------------------------------------------------------------------
Related Posts:
A new technique to study genetic changes that can lead to breast cancer could be one step closer. The University of Nottingham has received £15,000 from the charity Breast Cancer Campaign to fill in one of the research gaps identified by the country’s top breast cancer experts in a recent study carried out by the
Full Post: New technique to study the genetics of breast cancer
A study to assess the feasibility of undertaking a UK-based screening trial for lung cancer has been commissioned by the National institute for Health Research Health Technology Assessment (NIHR HTA) programme. Lung cancer kills more people worldwide than any other malignancy accounting for around 1.4 million deaths each year, and around 38,000 individuals are diagnosed
Full Post: Lung cancer screening feasibility study funded
Bowel cancer screening is predicted to save over two and a half thousand lives every year in the UK by 2025, according to new research published in the Journal of Medical Screening*. The Cancer Research UK funded study, which looked at the impact home testing kits could have on mortality rates, showed that deaths from
Full Post: Bowel cancer screening set to save thousands of lives
Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. While not the first to report a long-term decline in cancer mortality, Cutler’s is the first study to examine
Full Post: Are we finally winning the war on cancer?
Scientists at The Institute of Cancer Research have made significant progress in pinpointing two new risk factors associated with the most common childhood kidney cancer, known as Wilms tumour. The research published in Clinical Cancer Research today found that specific genetic changes in certain cells may cause childhood kidney cancer. Lead scientist, Dr Chris
Full Post: Scientists pinpoint two new risk factors for Wilms tumour --------------------------------------------------------------------------------------------
